AMGEN INC Operating Income Loss

• AMGEN INC showed an increase of +25.1% in Operating Income Loss from 2024 to 2025.
• This data is from AMGEN INC's annual report (Form 10-K), filed with the SEC on February 13, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), AMGEN INC's Operating Income Loss has grown by 74.1%.
• Historical annual values: Fiscal year 2025: $9.08 billion | Fiscal year 2024: $7.26 billion | Fiscal year 2023: $7.90 billion | Fiscal year 2022: $9.57 billion | Fiscal year 2021: $7.64 billion | Fiscal year 2020: $9.14 billion | Fiscal year 2019: $9.67 billion | Fiscal year 2018: $10.26 billion | Fiscal year 2017: $9.97 billion | Fiscal year 2016: $9.79 billion | Fiscal year 2015: $8.47 billion | Fiscal year 2014: $6.19 billion | Fiscal year 2013: $5.87 billion | Fiscal year 2012: $5.58 billion | Fiscal year 2011: $4.31 billion | Fiscal year 2010: $5.55 billion | Fiscal year 2009: $5.51 billion | Fiscal year 2008: $5.21 billion.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026